MDGL
NASDAQ
US
Madrigal Pharmaceuticals, Inc. - Common Stock
$546.89
▲ +$17.05
(+3.22%)
Vol 345K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$13.2B
ROE
-41.5%
Margin
-39.0%
D/E
54.30
Beta
-1.07
52W
$265–$615
Wall Street Consensus
23 analysts · Apr 20265
Strong Buy
15
Buy
3
Hold
0
Sell
0
Strong Sell
87.0%
Buy Rating
Price Chart
Similar Stocks
MRNA
Moderna Inc
$11.5B
INCY
Incyte Corp
P/E 16.3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33.0
$14.1B
IONS
Ionis Pharmaceuticals Inc
$12.8B
EXEL
Exelixis Inc
P/E 17.3
$11.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21.9
$11.4B
PRAX
Praxis Precision Medicines Inc
$7.4B
ARWR
Arrowhead Pharmaceuticals Inc
$9.0B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.69 | $-2.57 | $-1.88 |
| Sep 2025 | $-2.12 | $-4.96 | $-2.84 |
| Jun 2025 | $-3.71 | $-1.90 | +$1.81 |
| Mar 2025 | $-3.84 | $-3.32 | +$0.52 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -38.4% | -38.4% | -38.4% | -38.4% | -41.5% | -41.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -19.9% | -54.7% | -54.7% | -54.7% | -39.0% | -39.0% |
| Gross Margin | 95.7% | 96.3% | 96.3% | 96.3% | 95.2% | 95.2% |
| D/E Ratio | 17.01 | 17.01 | 17.01 | 17.01 | 54.30 | 54.30 |
| Current Ratio | 5.11 | 5.11 | 5.11 | 5.11 | 3.44 | 3.44 |
Key Ratios
ROA (TTM)
-26.2%
P/S (TTM)
17.86
P/B
8.9
EPS (TTM)
$-13.01
CF/Share
$-19.21
52W High
$615.00
52W Low
$265.00
$265.00
52-Week Range
$615.00
How does MDGL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
MDGL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
17.9
▲
39%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
8.9
▲
263%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
MDGL profitability vs Biotechnology peers
ROE
-41.5%
▲
38%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-39.0%
▲
86%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
95.3%
▲
21%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-26.2%
▲
44%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
MDGL financial health vs Biotechnology peers
D/E ratio
54.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.4
▼
23%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
-1.1
▼
211%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
MDGL fundamentals radar
MDGL
Peer median
Industry
MDGL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio